INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
CC

Canale-Theakston Carin

DirectorCIK 0001841613

EDGAR filingsOpen in network
Disclosed transactions7
Buys / sells0 / 0
Max Insider Score9
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D—
1,750 sh
Jan 7, 2026Jan 7, 2026
traded Jan 7, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Cidara Therapeutics, Inc.Director · Jan 7, 2026
9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D
—
875 sh
Jan 7, 2026
Jan 7, 2026
traded Jan 7, 2026
+0d
SEC FORM 4

Evidence

9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D—
1,400 sh
Jan 7, 2026Jan 7, 2026
traded Jan 7, 2026
+0dSEC FORM 4

Evidence

9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D—
2,125 sh
Jan 7, 2026Jan 7, 2026
traded Jan 7, 2026
+0dSEC FORM 4

Evidence

9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D—
2,125 sh
Jan 7, 2026Jan 7, 2026
traded Jan 7, 2026
+0dSEC FORM 4

Evidence

9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D—
11.1K sh
Jan 7, 2026Jan 7, 2026
traded Jan 7, 2026
+0dSEC FORM 4

Evidence

9
CC
Canale-Theakston CarinDirector
CDTXCidara Therapeutics, Inc.
Disposition to issuer
D—
16.0K sh
Jan 7, 2026Jan 7, 2026
traded Jan 7, 2026
+0dSEC FORM 4

Evidence